Department of Chemistry, Illinois Institute of Technology, Chicago, IL 60616, USA.
Analyst. 2019 Feb 25;144(5):1825-1830. doi: 10.1039/c8an02344a.
A disintegrin and metalloproteinase 17 (ADAM17) has become a novel biomarker and potential therapeutic target for the early detection and treatment of human cancers. In this work, by covalently attaching fluorescently labeled ADAM17 substrate peptide (Pep-FAM) molecules to carboxylated graphene oxide (cGO) and monitoring the cleavage of the peptide substrate by ADAM17, we developed a cGO-Pep-FAM fluorescence sensor for the rapid, sensitive and accurate detection of ADAM17. The sensor was highly sensitive with a detection limit of 17.5 picomolar. Furthermore, the sensor was selective: structure similar proteases such as ADAM9 and MMP-9 would not interfere with ADAM17 detection. In addition, simulated serum samples were successfully analyzed. Our developed cGO-Pep-FAM sensing strategy should find useful applications in disease diagnosis and drug screening.
解整合素金属蛋白酶 17（ADAM17）已成为人类癌症早期检测和治疗的新型生物标志物和潜在治疗靶点。在这项工作中，通过将荧光标记的 ADAM17 底物肽（Pep-FAM）分子共价连接到羧基化石墨烯氧化物（cGO）上，并监测 ADAM17 对肽底物的切割，我们开发了一种 cGO-Pep-FAM 荧光传感器，用于快速、灵敏和准确地检测 ADAM17。该传感器具有高灵敏度，检测限低至 17.5 皮摩尔。此外，该传感器具有选择性：结构相似的蛋白酶，如 ADAM9 和 MMP-9，不会干扰 ADAM17 的检测。此外，还成功分析了模拟血清样本。我们开发的 cGO-Pep-FAM 传感策略有望在疾病诊断和药物筛选中得到应用。
